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of CTE was 17% with an ACT <250 seconds compared to
9% with an ACT >250 ms. CTE did not occur in any control
patients.
Conclusions: The risk of asymptomatic CTE is ~15% in
patients undergoing RFCA of AF using an open irrigated-
tip catheter.
Perspective: Possible reasons for CTEs during RFCA of AF
are: pre-existing left atrial thrombus, char or thrombus on the
ablation catheter or at sites of ablated endocardium, air
emboli, or thrombus related to atrial stunning after cardiover-
sion. Although the clinical significance of asymptomatic
CTE is unclear, measures to minimize its occurrence (e.g.,
maintaining an ACT >350 seconds) are appropriate.   
Summary written by: Fred Morady, MD
Chest Compression-Only CPR by Lay Rescuers and
Survival From Out-of-Hospital Cardiac Arrest
Bobrow BJ, Spaite DW, Berg RA, et al.
JAMA 2010;304:1447–1454.
Study Question: Does compression-only cardiopulmonary
resuscitation (COCPR) by bystanders improve outcomes
after sudden cardiac arrest (SCA)? 
Methods: This was a prospective, observational cohort analysis
of 4,415 patients (mean age 65 years) with SCA in 2005-
2009 in Arizona. A public education campaign promoting
COCPR was initiated in Arizona in 2005. The 1º endpoint
was survival to hospital discharge.
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Radiofrequency Catheter Ablation of Atrial
Fibrillation: A Cause of Silent Thromboembolism?
Magnetic Resonance Imaging Assessment of
Cerebral Thromboembolism in Patients Undergoing
Ablation of Atrial Fibrillation
Gaita F, Caponi D, Pianelli M, et al.
Circulation 2010;122:1667–1673.
Study Question: What is the risk of cerebral thromboembolism
(CTE) during radiofrequency catheter ablation (RFCA) of
atrial fibrillation (AF)? 
Methods: Cerebral magnetic resonance imaging (MRI) was
performed before and 1 day after RFCA in 234 patients with
AF. An open irrigated-tip catheter was used for ablation.
Heparin was infused to maintain an activated clotting time
(ACT) ≥250 seconds. Low molecular weight heparin was
used as a bridge to therapeutic anticoagulation after ablation.
Sixty-five patients who underwent transthoracic cardioversion
served as a control group.
Results: One patient (0.4%) had a symptomatic transient
ischemic episode. An asymptomatic new cerebral ischemic
lesion was observed by MRI in 14% of patients. Independent
predictors of CTE were electrical or pharmacological conver-
sion to sinus rhythm and the ACT. Prevalence of CTE was
26% in patients who underwent cardioversion during the
ablation compared to 11% in patients who did not. Prevalence
SCANNING THE LITERATURE
Summaries of Key Journal Articles
Kim A. Eagle, MD, Editor-in-Chief, Journal Scan, Ann Arbor, MI
Christopher P. Cannon, MD, Editor-in-Chief, Cardiosource, Boston, MA
William F. Armstrong, MD, Ann Arbor, MI, David S. Bach, MD, Ann Arbor, MI, Ragavendra R.
Baliga, MBBS, Columbus, OH, Anna M. Booher, MD, Ann Arbor, MI, Timothy B. Cotts, MD, 
Ann Arbor, MI, Jennifer Cowger, MD, Ann Arbor, MI, Daniel T. Eitzman, MD, Ann Arbor, MI, 
James B. Froehlich, MD, Ann Arbor, MI, Caren S. Goldberg, MD, Ann Arbor, MI, Hitinder S. Gurm,
MBBS, Ann Arbor, MI, Jennifer C. Hirsch, MD, Ann Arbor, MI, Elizabeth Anne Jackson, MD, 
Ann Arbor, MI, Fred Morady, MD, Ann Arbor, MI, Debabrata Mukherjee, MD, El Paso, TX,
Himanshu J. Patel, MD, Ann Arbor, MI, John E. Rectenwald, MD, MS, Ann Arbor, MI, Melvyn
Rubenfire, MD, Ann Arbor, MI, Associate Editors, Cardiosource
no training and can be more readily guided by dispatchers
over the telephone.
5: Initiate chest compressions before giving rescue breaths
(C-A-B rather than A-B-C). Chest compressions can be
started immediately. Beginning CPR with 30 compressions
rather than 2 ventilations leads to a shorter delay to first
compression.
6: There is an increased focus on methods to ensure that
high-quality CPR is performed. Adequate chest compres-
sions require appropriate depth and rate, allowing complete
recoil of the chest after each compression, minimizing
pauses in compressions and avoiding excessive ventilation.
Recommended depth of compression for adult victims has
increased to at least 2 inches.
7: Minimize the importance of pulse checks by health care
providers; detection of a pulse can be difficult, especially
when blood pressure is abnormally low or absent. Health
care providers should take no more than 10 seconds to
determine if a pulse is present. 
8: For the best chance of survival, three actions must occur
within the first moments of a cardiac arrest: activation of the
EMS system, provision of CPR, and operation of a defibril-
lator.
9: Many tasks performed by health care providers during
resuscitation attempts can be performed concurrently by an
integrated team of highly trained rescuers in appropriate set-
tings. Health care provider training should focus on building
the team as each member arrives or quickly delegating roles if
multiple rescuers are present.
10: Objectives of post–cardiac arrest care include: optimizing
cardiopulmonary function and vital organ perfusion after
return of spontaneous circulation; transportation to an appro-
priate hospital or critical care unit with a comprehensive
post–cardiac arrest treatment system of care; identification and
intervention for acute coronary syndromes; temperature con-
trol to optimize neurologic recovery; and anticipation,
treatment, and prevention of multiple organ dysfunction.   
Summary written by: Debabrata Mukherjee, MD
Cardiovascular Surgery
Transcatheter Aortic-Valve Implantation for Aortic
Stenosis in Patients Who Cannot Undergo Surgery 
Leon MB, Smith CR, Mack M, et al., on behalf of the PARTNER
Trial Investigators.
N Engl J Med 2010;363:1597–1607.
Study Question: What is the outcome of patients with severe
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Results: Fifteen percent of patients received conventional
bystander CPR, 19% received COCPR, and 66% received
neither. Overall survival to hospital discharge was 7.1%.
COCPR was a significant independent predictor of survival
compared to no CPR (odds ratio [OR], 1.6) and compared to
conventional CPR (OR, 1.6). The percentage of patients who
survived with good neurologic status was significantly higher
in the COCPR group (7.6%) than the conventional CPR
(5.2%) or no-CPR group (3.0%).
Conclusions: Compared to no CPR or conventional CPR,
bystander COCPR significantly improves outcomes after
SCA.
Perspective: COCPR is associated with improved survival after
SCA because it avoids several problems associated with con-
ventional CPR, including: 1) cessation of cardiac output
during interruptions in chest compressions, 2) the long inter-
val needed to restore cardiac output after resumption of chest
compressions, 3) reduction in venous return associated with
positive pressure ventilation, and 4) reluctance of bystanders
to perform mouth-to-mouth ventilation.   
Summary written by: Fred Morady, MD
Part 1: Executive Summary. 2010 American Heart
Association Guidelines for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care
Field JM, Hazinski MF, Sayre MR, et al.
Circulation 2010;122:S640–S656.
Perspective: The following are 10 points to remember about
these guidelines:
1: The newest development in the 2010 American Heart
Association  Guidelines for Cardiopulmonary Resuscitation
(CPR) and Emergency Cardiovascular Care is a change in
the basic life support (BLS) sequence of steps from “A-B-
C” (Airway, Breathing, Chest compressions) to “C-A-B”
(Chest compressions, Airway, Breathing) for adults and
pediatric patients (excluding newborns). 
2: The etiology of neonatal arrests is nearly always asphyxia.
Therefore, the A-B-C sequence has been retained for resus-
citation of neonates unless there is a known cardiac etiology. 
3: The BLS algorithm has been simplified, and “Look,
Listen, and Feel” has been removed from the algorithm.
Performance of these steps is inconsistent and time consum-
ing. The 2010 guidelines stress immediate activation of the
emergency response system and starting chest compressions
for any unresponsive adult victim with no breathing or no
normal breathing.
4: Encourage hands-only (compression-only) CPR for the
untrained lay rescuer. It is easier to perform by those with
2: A significant portion of patients who require AVR do not
undergo the procedure, mainly due to a physician assess-
ment that comorbidities or advanced age preclude them. 
3: Transcatheter aortic valve implantation (TAVI) is a new
procedure designed to perform AVR through a minimally
invasive approach without need for cardiopulmonary bypass.
4: The majority of patients studied included those typically
considered either high-risk or nonoperative candidates for
conventional AVR.
5: The operation, depending on the valve chosen, can be
done through a transfemoral approach or a small chest inci-
sion transapical off-pump approach, resulting in an 89%
survival at 30 days in published trials. More recent studies
have suggested 30-day TAVI survival rates as high as 92-
97%.
6: The hemodynamics of TAVI accessed by Doppler
echocardiography appear similar to conventional AVR.
Mean TAVI transvalvular gradients are typically <15 mm in
short-term follow-up. In contrast, a significant difference
between AVR and TAVI is paravalvular regurgitation that
varies between mild to moderate in severity.
7: Vascular complications appear to be an important deter-
minant of early morbidity and mortality. These are
secondary to the size of the devices in relation to size of
access vessels of the patient or the presence of significant
atheromatous burden in this elderly patient group. 
8: Randomized prospective trials lack conventional AVR
candidates. The results of TAVI reported thus far cannot be
generalized to this patient group.
9: The recent PARTNER trial suggested benefit of TAVI in
patients considered high-risk for conventional AVR.
10: Improvements in devices and valves as well as delivery
mechanisms will likely improve the results of TAVI.   
Summary written by: Himanshu J. Patel, MD
Variation in Use of Blood Transfusion in Coronary
Artery Bypass Graft Surgery 
Bennett-Guerrero E, Zhao Y, O’Brien SM, et al.
JAMA 2010;304:1568–1575.
Study Question: What is the variation in use of perioperative
blood products among patients undergoing coronary artery
bypass grafting (CABG)? 
Methods: The authors used the Society of Thoracic Surgeons
database to evaluate the use of blood products in 102,470
patients undergoing primary isolated on-pump CABG sur-
gery in 2008 at 798 sites in the United States.
aortic valve stenosis who are not candidates for valve surgery
and are treated with transcatheter aortic-valve implantation
(TAVI)?   
Methods: The PARTNER trial investigators randomized 358
patients who were deemed nonsurgical candidates to stan-
dard therapy (including balloon aortic valvuloplasty) or
transfemoral TAVI. The primary endpoint was all-cause
mortality.
Results: Within the first 24 hours of TAVI, two patients died,
three had major strokes, and one had a valve embolization. At
30 days, there was no difference in the mortality of the TAVI
group (5%) compared with the standard-therapy group (2.8%).
However, the TAVI arm had a higher incidence of major
strokes at 30 days (5.0% vs. 1.1%, p = 0.06) and major vascular
complications (16.2% vs. 1.1%, p < 0.001). The 1-year mortal-
ity was significantly lower in the TAVI arm (30.7% vs. 50.7%;
p < 0.001). The composite endpoint of death from any cause
or repeat hospitalization was also lower with TAVI (42.5% vs.
71.6%; p < 0.001). TAVI was associated with a lower degree
of cardiac symptoms and better functional status among the
survivors at 1 year.
Conclusions: Among patients with aortic stenosis who are not
deemed surgical candidates, TAVI is associated with dra-
matic improvement in survival compared with standard
therapy.
Perspective: This study confirms that untreated severe aortic
stenosis has a poor outcome, and TAVI is associated with a
dramatic improvement in survival and symptoms. While
TAVI was associated with a high risk of stroke and vascular
complications in this trial, these rates are likely to improve
with better technology and greater operator experience. The
absolute reduction in mortality seen in this trial is unparal-
leled in the modern era and establishes TAVI as the
standard of care in patients with aortic stenosis, who are not
surgical candidates.  
Summary written by: Hitinder S. Gurm, MBBS
Percutaneous Heart Valve Replacement for Aortic
Stenosis: State of the Evidence
Coeytaux RR, Williams JW Jr, Gray RN, Wang A.
Ann Intern Med 2010;153:314–324.
Perspective: The following are 10 points to remember about
percutaneous heart valve replacement for aortic stenosis:
1: Patients with severe symptomatic aortic stenosis have a
dismal prognosis with maximum medical therapy. Two-year
mortality is approximately 50% and open surgical aortic
valve replacement (AVR) is the only treatment demon-
strated to improve symptoms and life expectancy. 




Results: At the 408 hospitals performing at least 100 on-
pump CABG operations (82,446 cases), rates of blood
transfusion ranged from 7.8-92.8% for red blood cells
(RBCs), 0-97.5% for fresh-frozen plasma, and 0.4-90.4%
for platelets. After adjustment for patient-level risk factors,
hospital transfusion rates varied by geographic location
(highest in West south central region, p = 0.007), academic
status (p = 0.03), and hospital volume (p < 0.001). Only
11% of the variation in hospital risk-adjusted RBC use was
explained by these three characteristics, and case mix
accounted for another 20%.
Conclusions: There is wide variation in blood product use in
patients undergoing CABG in the United States.
Perspective: The variation in transfusion in patients undergo-
ing CABG was highlighted approximately 2 decades ago
(Goodnough LT, et al., JAMA 1991;265:86-90) and contin-
ues to be a problem today. Blood transfusion is expensive
and may have negative impact on outcome. Variation is
mostly related to practice patterns and invokes the need for
local multidisciplinary blood conservation efforts to optimize
blood product use.  
Summary written by: Hitinder S. Gurm, MBBS
General Cardiology
Effect of a Free Prepared Meal and Incentivized
Weight Loss Program on Weight Loss and Weight
Loss Maintenance in Obese and Overweight
Women: A Randomized Controlled Trial 
Rock CL, Flatt SW, Sherwood NE, Karanja N, Bilge Pakiz, Thomson
CA.
JAMA 2010;Oct 9:[Epub ahead of print]. 
Study Question: Does a free meal plan, together with an incen-
tivized weight loss program, allow women to lose significant
amounts of weight and maintain that weight loss long-term? 
Methods: Women over the age of 18 with a body mass index
between 25 and 40 who were not pregnant were included. In
this controlled trial, women were randomized to either in-
person center-based or telephone-based one-to-one weight
loss counseling together with free prepared meals or usual
care. Weight was measured over a 2-year period. Meals were
low-fat, energy reduced. Additional goals included regular
physical activity of 30 minutes per day for 5 or more days of
the week.
Results: A total of 442 women were included (mean age 44
years). At 2 years, weight data were available for 407 women
(92% of the subjects). Based on an intention-to-treat analysis,
mean weight loss was 7.4 kg or 7.9% of initial weight at 24
months for the center-based group. Weight loss was 6.2 kg or
6.8% for the telephone-based group, and 2.0 kg or 2.1% for
the usual care control group after 24 months. The difference
between the three groups was statistically significant (p <
0.001). All groups demonstrated improvements in physical fit-
ness and reductions in total cholesterol; however, no
intervention effect was observed. Levels of C-reactive protein
were reduced to a greater degree among women in the two
intervention arms compared to usual care. 
Conclusions: A structured weight loss plan with free meals
resulted in greater weight loss and maintenance of weight
loss over 2 years compared to usual care.
Perspective: These data suggest that a structured plan including
prepared meals may assist overweight and obese adults to lose
weight. A careful transition from prepared meals to the sub-
ject’s ad lib diet, together with continued counselor support, is
likely key to the continued maintenance of weight loss
observed in this study.  
Summary written by: Elizabeth Jackson, MD
Lasofoxifene and Cardiovascular Events in
Postmenopausal Women With Osteoporosis. 
Five-Year Results From the Postmenopausal
Evaluation and Risk Reduction With Lasofoxifene
(PEARL) Trial 
Ensrud K, LaCroix A, Thompson JR, et al.
Circulation 2010;122:1716–1724.
Study Question: Does lasofoxifene affect the risk for cardiovas-
cular events in postmenopausal women?
Methods: Data from the PEARL trial were included in this
analysis. Postmenopausal women between the ages of 60 and
80 years with osteoporosis were included from 113 study sites,
enrolled between November 2001 and February 2003.
Women were randomized to lasofoxifene 0.25 mg, lasofox-
ifene 0.5 mg, or placebo. Primary outcomes were coronary
heart disease (CHD) events or death.
Results: A total of 8,556 women were randomized into the
three treatment arms (2,852 per group; mean age 67 years).
The median of 10-year risk for developing CHD was 7%.
Over a median follow-up of 4.96 years, major CHD events
occurred in 95 women in the placebo group, 73 women in the
lasofoxifene 0.25 mg/day group, and 65 women in the laso-
foxifene 0.50 mg/day group. Compared with placebo, women
in the lasofoxifene 0.5 mg/day group had significantly fewer
CHD events (hazard ratio [HR], 0.68). Risk of coronary
revascularization was less in this group compared to placebo
(HR, 0.56), as was risk of hospitalization for unstable angina
(HR, 0.55), and diagnosis of new ischemic heart disease (HR,
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Perspective: These findings suggest the possibility that severe
hypoglycemia has either a direct causal link with adverse
outcomes, or is a marker of vulnerability to a wide range of
adverse clinical outcomes. The presence of severe hypo-
glycemia should raise clinical suspicion of the patient’s
susceptibility to adverse outcomes and prompt action to
reduce/minimize cardiovascular risk with appropriate evi-
dence-based therapies.  
Summary written by: Debabrata Mukherjee, MD
Multicenter Validation of the Diagnostic Accuracy
of a Blood-Based Gene Expression Test for
Assessing Obstructive Coronary Artery Disease in
Nondiabetic Patients
Rosenberg S, Elashoff MR, Beineke P, et al., on behalf of the 
PREDICT (Personalized Risk Evaluation and Diagnosis in the
Coronary Tree) Investigators.
Ann Intern Med 2010;153:425–434.
Study Question: What is the predictive ability of a 23-gene
expression-based classification test for diagnosis of obstructive
coronary artery disease (CAD) in nondiabetic patients?  
Methods: This multicenter prospective trial included 526 non-
diabetic patients with a clinical indication for coronary
angiography; blood samples were obtained before angioplasty.
Receiver-operating characteristic (ROC) analysis of classifier
score measured by real-time polymerase chain reaction, addi-
tivity to clinical factors, and reclassification of patient disease
likelihood versus disease status defined by quantitative coro-
nary angiography was performed. Obstructive CAD was
defined as 50% or greater stenosis in one or more major coro-
nary arteries.
Results: The area under the ROC curve (AUC) was 0.70 ±
0.02 (p < 0.001); the test added to clinical variables
(Diamond–Forrester method) (AUC, 0.72 with the test vs.
0.66 without; p = 0.003) and added somewhat to an
expanded clinical model (AUC, 0.745 with the test vs. 0.732
without; p = 0.089). The test improved net reclassification
over both the Diamond–Forrester method and the expanded
clinical model (p < 0.001). At a score threshold that corre-
sponded to a 20% likelihood of obstructive CAD (14.75), the
sensitivity and specificity were 85% and 43% (yielding a neg-
ative predictive value of 83% and a positive predictive value of
46%), with 33% of patient scores below this threshold. 
Conclusions: A noninvasive whole-blood test based on gene
expression and demographic characteristics may be useful
for assessing obstructive CAD in nondiabetic patients.
Perspective: This study found a modest improvement in pre-
dicting CAD by using a gene test score compared with a
clinical measure (Diamond–Forrester method), but was no
0.52). No significant differences were observed for coronary
death or nonfatal MI. The effectiveness of lasofoxifene 0.5
mg/day in reducing CHD events was similar across strata of
major cardiovascular risk factors. 
Conclusions: Lasofoxifene 0.5 mg/day reduced the risk of
CHD events among postmenopausal women with osteo-
porosis, including women with and without cardiovascular
disease risk factors.
Perspective: The reduction in CHD risk appears to be pre-
dominately for lower risk of coronary revascularization
procedures. These data suggest that lasofoxifene can be used
to treat osteoporosis in postmenopausal women, in particular
among women with risk factors for CHD. Since women
with a prior history of CHD were excluded, further studies
are warranted to address that population.  
Summary written by: Elizabeth Jackson, MD
Severe Hypoglycemia and Risks of Vascular Events
and Death 
Zoungas S, Patel A, Chalmers J, et al., on behalf of the ADVANCE
Collaborative Group.
N Engl J Med 2010;363:1410–1418. 
Study Question: What is the relationship between severe
hypoglycemia and adverse clinical outcomes? 
Methods: The ADVANCE trial investigators examined the
associations between severe hypoglycemia and the risks of
macrovascular or microvascular events and death among
11,140 patients with type 2 diabetes, using Cox proportional-
hazards models with adjustment for covariates measured at
baseline and after randomization.
Results: During a median follow-up of 5 years, 231 patients
(2.1%) had at least one severe hypoglycemic episode; 150
had been assigned to intensive glucose control (2.7% of the
5,571 patients in that group), and 81 had been assigned to
standard glucose control (1.5% of the 5,569 patients in that
group). The median times from the onset of severe hypo-
glycemia to the first major macrovascular and microvascular
event and death were 1.56 years, 0.99 years, and 1.05 years,
respectively. During follow-up, severe hypoglycemia was
associated with a significant increase in the adjusted risks of
major macrovascular events (hazard ratio [HR], 2.88), major
microvascular events (HR, 1.81), death from a cardiovascu-
lar cause (HR, 2.68), and death from any cause (HR, 2.69).
Similar associations were apparent for a range of nonvascular
outcomes, including respiratory, digestive, and skin condi-
tions (p < 0.01 for all comparisons). 
Conclusions: Severe hypoglycemia was strongly associated
with increased risks of a range of adverse clinical outcomes.




better when compared with an expanded set of clinical meas-
ures. Further studies are needed to evaluate the contribution
of gene test scores in accurately predicting CAD. For now,
this test remains a research tool pending further validation and
improvement in predictive ability.  
Summary written by: Debabrata Mukherjee, MD
Heart Failure/Transplant
Serial Measurement of Growth-Differentiation
Factor-15 in Heart Failure: Relation to Disease
Severity and Prognosis in the Valsartan Heart
Failure Trial
Anand IS, Kempf T, Rector TS, et al.
Circulation 2010;122:1387–1395.
Study Question: Do circulating levels of growth-differentiation
factor-15 (GDF-15) predict outcomes in patients with heart
failure?
Methods: Circulating concentrations of GDF-15 were meas-
ured at baseline (n = 1,734) and at 12 months (n = 1,517) in
patients randomized in the Valsartan Heart Failure Trial
(Val-HeFT). GDF-15 levels at baseline ranged from 259 to
25,637 ng/L and were abnormally high (>1200 ng/L) in
85% of patients.
Results: Higher levels of GDP-15 were associated with fea-
tures of worse heart failure and biomarkers of
neurohormonal activation, inflammation, myocyte injury,
and renal dysfunction. Baseline GDF-15 levels (per 100
ng/L) were associated with the risks of mortality (hazard
ratio [HR], 1.017) and first morbid event (HR, 1.020). In a
comprehensive multiple-variable Cox regression model that
included clinical prognostic variables, B-type natriuretic
peptide, high-sensitivity C-reactive protein, and high-sensi-
tivity troponin T, GDF-15 remained independently
associated with mortality (HR, 1.007), but not first morbid
event. At 12 months, the GDF-15 levels had increased by a
similar amount in the placebo and valsartan groups.
Increases in GDF-15 over 12 months were independently
associated with the risks of future mortality and first morbid
event after adjustment for other variables.
Conclusions: GDF-15 reflects information from several
pathological pathways and provides independent prognostic
information in heart failure. GDF-15 levels increase over
time, suggesting that GDF-15 reflects a pathophysiological
axis that is not completely addressed by the therapies pre-
scribed in Val-HeFT.
Perspective: Several previous studies have demonstrated that
GDF-15 may be of prognostic value in patients with coronary
disease. The current study extends the potential use of this
biomarker to patients with heart failure. As more is learned
about the pathophysiology of GDF-15, it may become useful
as an informative marker to risk stratify patients with cardio-
vascular disease and guide specific therapeutic interventions.  
Summary written by: Daniel T. Eitzman, MD
Unrecognised Myocardial Infarction and Long-
Term Risk of Heart Failure in the Elderly: The
Rotterdam Study
Leening MJ, Elias-Smale SE, Felix JF, et al.
Heart 2010;96:1458–1462.
Study Question: What is the long-term risk of heart failure in
patients with electrocardiographic (ECG) evidence of unrec-
ognized myocardial infarction (MI)? 
Methods: This was a prospective cohort study of 6,305 eligi-
ble subjects ages ≥55 years without prevalent heart failure
residing in The Netherlands. Patients were placed into one
of three categories: 1) history of recognized MI (with or
without ECG changes), 2) no history of MI and no evi-
dence of Q waves on ECG, and 3) no history of MI, but
evidence of Q waves on ECG. During follow-up, patients
who were classified as having definite or probable heart fail-
ure were considered incident cases.
Results: During a mean follow-up of 13.2 years, there were
2,105 deaths and 823 incident cases of heart failure. The
incidences of heart failure for patients with no history of
MI, unrecognized MI, and prior known MI were 17%, 37%,
and 39%, respectively. Compared to men without a prior
MI, men with recognized and unrecognized MI had 2.6 and
2.4 increased risk (hazard ratio) of developing heart failure,
respectively. Women with recognized MI had 2.8 increased
hazard of heart failure development, but those with unrecog-
nized MI had no significant increased heart failure risk (1.2)
when compared with women without MI.
Conclusions: Unrecognized ECG evidence of MI in men, but
not women, is associated with a risk for heart failure devel-
opment equivalent to men with recognized MI.
Perspective: This study suggests that differences exist in the
risk of heart failure development between men and women
with ECG evidence of ‘silent’ Q-wave MIs, perhaps due to
artifactual Q waves in women arising from breast tissue
and/or ECG placement. Women with unrecognized MI
were also more likely to be obese than those with recog-
nized MIs. This study supports prior data demonstrating
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limitations with cardiovascular testing interpretation and
cardiovascular prognosis assessment in women compared
with men. Clinical trials should strive to appropriately rep-
resent the female sex.
Summary written by: Jennifer Cowger, MD
Interventional Cardiology
Proton-Pump Inhibitors Are Associated With
Increased Cardiovascular Risk Independent of
Clopidogrel Use: A Nationwide Cohort Study
Charlot M, Ahlehoff O, Norgaard ML, et al.
Ann Intern Med 2010;153:378–386.
Study Question: What is the risk for adverse cardiovascular out-
comes related to concomitant use of proton pump inhibitors
(PPIs) and clopidogrel compared with that of PPIs alone in
adults hospitalized for myocardial infarction (MI)?  
Methods: This was a nationwide cohort study based on linked
administrative registry data. The primary outcome was a com-
posite of rehospitalization for MI or stroke or cardiovascular
death. Patients were examined at 7, 14, 21, and 30 days after
MI. Follow-up was 1 year.
Results: Of 56,406 patients, 9,137 (16.2%) were rehospital-
ized for MI or stroke or experienced cardiovascular death.
Of the 24,702 patients (43.8%) who received clopidogrel,
6,753 (27.3%) received concomitant PPIs. The hazard ratio
for cardiovascular death or rehospitalization for MI or stroke
for concomitant use of a PPI and clopidogrel among the
cohort assembled at day 30 after discharge was 1.29. The
corresponding ratio for use of a PPI in patients who did not
receive clopidogrel was 1.29. No statistically significant
interaction occurred between a PPI and clopidogrel 
(p = 0.72). 
Conclusions: PPIs seem to be associated with increased risk for
adverse cardiovascular outcomes after discharge, regardless of
clopidogrel use for MI. 
Perspective: This study found no evidence that concomitant
PPI therapy increases risk for adverse cardiovascular events
in patients who receive clopidogrel and is consistent with
the results of the COGENT trial. PPIs appear to be associ-
ated with an increased risk for adverse cardiovascular
outcomes regardless of clopidogrel use, and this is likely
explained by unmeasured confounders. These results seem
to refute concerns about increased risk for ischemic events
during concomitant PPI and clopidogrel therapy, and pro-
vide reassurance about safety of PPIs in patients on dual
antiplatelet therapy.
Summary written by: Debabrata Mukherjee, MD
10-Year Stroke Prevention After Successful 
Carotid Endarterectomy for Asymptomatic Stenosis
(ACST-1): A Multicentre Randomised Trial
Halliday A, Harrison M, Hayter E, et al., on behalf of the
Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group.
Lancet 2010;376:1074–1084.
Study Question: What is the long-term benefit of carotid
endarterectomy (CEA) in patients with asymptomatic carotid
disease? 
Methods: The authors reported the 10-year outcome of
patients randomized to immediate CEA versus best medical
therapy (with CEA reserved for symptomatic disease or per
the advice of the treating physician) in the ACST-1 trial.
Primary outcomes were perioperative mortality and morbidity
(death or stroke within 30 days) and non-perioperative stroke.
Results: The study enrolled 3,120 patients between 1993
and 2003 from 126 centers in 30 countries. The risk of
periprocedural stroke or death in patients undergoing CEA
was 3%. Approximately one-half of the events were major
disabling strokes or death (n = 34), while the rest were
nondisabling strokes (n = 26). Excluding perioperative
events and nonstroke mortality, stroke risk was dramatically
lower with CEA at 5 years (4.1% vs. 10.0%) and 10 years
(10.8% vs. 16.9%, p < 0.0001). The benefit was independ-
ent of medication use and was significant in patients who
were on lipid-lowering therapy (annualized stroke rate 0.7
vs. 1.3% per year) and those not on lipid-lowering agents
(annualized stroke rate 1.8 vs. 3.3% per year). Benefit was
seen in all patient subgroups except those who were older
than 75 years of age. 
Conclusions: Successful CEA for asymptomatic patients
younger than 75 years of age reduces long-term stroke risks. 
Perspective: This study provides robust evidence to support
CEA for asymptomatic disease. The persistent reduction in
long-term risk of stroke with CEA is additive to the benefit
seen with medical therapy, and the absolute benefit with
CEA is much greater than that seen with medical therapy.
High periprocedural risk of death or stroke, or poor long-term
survival can negate any long-term benefit of CEA, and it is
important that the procedure be performed by experienced
surgeons in patients with life expectancy greater than 5 years.
Summary written by: Hitinder S. Gurm, MBBS





Fondaparinux for the Treatment of Superficial-Vein
Thrombosis in the Legs
Decousus H, Prandoni P, Mismetti P, et al., on behalf of the 
CALISTO Study Group.
N Engl J Med 2010;363:1222–1232.
Study Question: What is the efficacy and safety of fondaparinux
in reducing symptomatic venous thromboembolic complica-
tions or death from any cause in patients with acute, isolated
superficial-vein thrombosis of the legs?  
Methods: The CALISTO investigators randomly assigned
3,002 patients to receive either fondaparinux, administered
subcutaneously at a dose of 2.5 mg once daily, or placebo for
45 days. The primary efficacy outcome was a composite of
death from any cause or symptomatic pulmonary embolism,
symptomatic deep-vein thrombosis, or symptomatic extension
to the saphenofemoral junction or symptomatic recurrence of
superficial-vein thrombosis at day 47. The main safety out-
come was major bleeding. The patients were followed until
day 77. 
Results: The primary efficacy outcome occurred in 13 of 1,502
patients (0.9%) in the fondaparinux group and 88 of 1,500
patients (5.9%) in the placebo group (relative risk reduction
with fondaparinux, 85%). The incidence of each component of
the primary efficacy outcome was significantly reduced in the
fondaparinux group compared with the placebo group, except
for the outcome of death (0.1% in both groups). The rate of
pulmonary embolism or deep-vein thrombosis was 85% lower
in the fondaparinux group than in the placebo group (0.2% vs.
1.3%). Similar risk reductions were observed at day 77. Major
bleeding occurred in one patient in each group. The incidence
of serious adverse events was 0.7% with fondaparinux and
1.1% with placebo. 
Conclusions: Fondaparinux at a dose of 2.5 mg once a day for
45 days was effective in the treatment of patients with acute,
symptomatic superficial-vein thrombosis of the legs, and did
not have serious side effects. 
Perspective: The cost-effectiveness of fondaparinux remains to
be evaluated, taking into account the clinical events that may
be prevented with treatment and the direct cost of fonda-
parinux. Additional studies are therefore indicated to
document the costs, the effects on quality of life, and the cost-
effectiveness of fondaparinux for this indication to reach a
consensus regarding its worthiness. Until such data are avail-
able and consensus is reached, it seems premature to
recommend that fondaparinux be used routinely in the treat-
ment of superficial-vein thrombosis.
Summary written by: Debabrata Mukherjee, MD
Effect of Home Testing of International Normalized
Ratio on Clinical Events
Matchar DB, Jacobson A, Dolor R, et al., on behalf of the THINRS
Executive Committee and Site Investigators.
N Engl J Med 2010;363:1608–1620.
Study Question: What is the efficacy of self-testing of interna-
tional normalized ratio (INR) in reducing the risk of a major
event (stroke, major bleeding episode, or death)? 
Methods: The investigators randomly assigned 2,922 patients
who were taking warfarin because of mechanical heart valves
or atrial fibrillation and who were competent in the use of
point-of-care INR devices to either weekly self-testing at
home or monthly high-quality testing in a clinic. The primary
endpoint was the time to a first major event (stroke, major
bleeding episode, or death).  
Results: The patients were followed for 2.0-4.75 years. Time
to the first primary event was not significantly longer in the
self-testing group than in the clinic-testing group (p =
0.14). The two groups had similar rates of clinical outcomes
except that the self-testing group reported more minor
bleeding episodes. Over the entire follow-up period, the
self-testing group had a small but significant improvement
in the percentage of time during which the INR was within
the target range (absolute difference between groups, 3.8
percentage points; p < 0.001). At 2 years of follow-up, the
self-testing group also had a small but significant improve-
ment in patient satisfaction with anticoagulation therapy 
(p = 0.002) and quality of life (p < 0.001). 
Conclusions: The study results do not support the superiority of
self-testing over clinic testing in reducing the risk of stroke,
major bleeding episode, and death among patients taking
warfarin therapy.
Perspective: In light of the poor record of usual care and the
value of anticoagulation in preventing major events, self-test-
ing may be considered for patients whose access to
high-quality anticoagulation care is limited by disability, geo-
graphic distance, or other factors, if the alternative would be
to withhold a highly effective therapy. Newer antithrombotics
such as dabigatran may obviate the need for routine monitor-
ing in the future.
Summary written by: Debabrata Mukherjee, MD
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